• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Talphera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/24/24 5:24:09 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLPH alert in real time by email
    acrx20240624_8k.htm
    false 0001427925 0001427925 2024-06-24 2024-06-24
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): June 24, 2024
     
    TALPHERA, INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware
     
    001-35068
     
    41-2193603
    (State of incorporation)
     
    (Commission File No.)
     
    (IRS Employer Identification No.)
     
    1850 Gateway Drive, Suite 175
    San Mateo, CA 94404
    (Address of principal executive offices and zip code)
     
    Registrant’s telephone number, including area code: (650) 216-3500
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.001 par value
    TLPH
    The Nasdaq Global Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.02         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    As described under Item 5.07 of this Current Report on Form 8-K, on June 24, 2024, at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Talphera, Inc. (the “Company”), the Company’s stockholders, upon the recommendation of the Company’s Board of Directors (the “Board”), approved an amendment and restatement of the Company’s Amended and Restated 2020 Equity Incentive Plan (the “2020 EIP”), and an amendment and restatement of the Company’s Amended and Restated the Company’s 2011 Employee Stock Purchase Plan (the “2011 ESPP”).
     
    A summary of both the 2020 EIP and 2011 ESPP is set forth in the Company’s definitive proxy statement on Schedule 14A filed on April 29, 2024 for the Annual Meeting. That summary is qualified in its entirety by reference to the terms of the 2020 EIP and 2011 ESPP, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
     
    Item 5.07         Submission of Matters to a Vote of Security Holders.
     
    The Annual Meeting of the Company was held on June 24, 2024. Proxies for the Annual Meeting were solicited by the Board pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition. At the Annual Meeting, a total of 9,562,803 shares were represented in person or by proxy out of the 16,992,977 shares of common stock entitled to vote as of April 26, 2024, the record date for the Annual Meeting. The final votes on the proposals presented at the Annual Meeting were as follows:
     
    Proposal No. 1
     
    Adrian Adams and Jill Broadfoot were elected as Class I directors, by a plurality of the votes entitled to vote on the election of directors, to hold office until the 2027 Annual Meeting of Stockholders by the following vote:
     
    Nominee
     
    For
       
    Withheld
       
    Broker Non-Votes
     
    Adrian Adams
      5,249,851     320,764     3,992,188  
    Jill Broadfoot
      5,253,667     316,948     3,992,188  
     
    In addition to the directors elected above, Vincent J. Angotti, Abhinav Jain, and Stephen J. Hoffman, M.D., Ph.D. will continue to serve as directors until the 2025 Annual Meeting of Stockholders, and Marina Bozilenko and Mark Wan will continue to serve as directors until the 2026 Annual Meeting of Stockholders, in each case until their successors are elected and qualified, or until their earlier death, resignation or removal.
     
    Proposal No. 2
     
    The selection by the Audit Committee of the Board of BPM LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024 was ratified by the following vote:
     
    For
       
    Against
       
    Abstain
       
    Broker Non-Votes
     
    9,149,535     329,576     83,692     —  
     
    Proposal No. 3
     
    The compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, compensation tables and narrative discussion was approved, on an advisory basis, by the following vote:
     
    For
       
    Against
       
    Abstain
       
    Broker Non-Votes
     
    4,602,372       584,372       383,871       3,992,188  
     
     

     
     
    Proposal No. 4
     
    The Company’s 2020 EIP was approved, by the following vote:
     
    For
       
    Against
       
    Abstain
       
    Broker Non-Votes
     
    4,617,931     577,333     375,351     3,992,188  
     
    Proposal No. 5
     
    The Company’s 2011 ESPP was approved, by the following vote:
     
    For
       
    Against
       
    Abstain
       
    Broker Non-Votes
     
    4,684,340     530,324     355,951     3,992,188  
     
    Item 9.01         Financial Statements and Exhibits.
     
    (d) Exhibits
              
    Exhibit No. Description
    10.1+
    Amended and Restated 2020 Equity Incentive Plan
    10.2+
    Amended and Restated 2011 Employee Stock Purchase Plan
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     

    + Indicates management contract or compensatory plan
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
     
    Date: June 24, 2024
    TALPHERA, INC.
      
     
    By:  
    /s/ Raffi Asadorian
       
    Raffi Asadorian
       
    Chief Financial Officer
     
     
    Get the next $TLPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLPH

    DatePrice TargetRatingAnalyst
    1/28/2025$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TLPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:28:48 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:27:03 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Engineering Officer Dasu Badri N covered exercise/tax liability with 3,127 shares and bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 76% to 73,884 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:25:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

    SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor and analyst event on Monday, March 23, 2026 at 11:00 AM ET featuring Blaithin McMahon, PhD, MBBChr (Medical University of South Carolina) and Joao Teixeira, MD (University of New Mexico), principal investigators in Talphera's NEPHRO CRRT study evaluating Niyad for continuous renal replacement therapy (CRRT). To register, click here.The experts will discuss their experience with CRRT, the anticoagulan

    3/18/26 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Nantahala Capital Management, Llc

    4 - TALPHERA, INC. (0001427925) (Issuer)

    3/17/26 4:30:38 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:28:48 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:27:03 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    SEC Filings

    View All

    Talphera Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - TALPHERA, INC. (0001427925) (Filer)

    3/16/26 8:30:44 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - TALPHERA, INC. (0001427925) (Filer)

    3/13/26 4:05:21 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.

    SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)

    2/17/26 1:03:18 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Talphera with a new price target

    Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

    1/28/25 7:17:45 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Leadership Updates

    Live Leadership Updates

    View All

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $TLPH
    Financials

    Live finance-specific insights

    View All

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

    SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast lin

    11/5/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care